AI assistant
Jazz Pharmaceuticals plc — Director's Dealing 2023
Aug 15, 2023
30751_dirs_2023-08-15_891d873a-366b-40d4-9749-53d1e6c134da.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2023-08-11
Reporting Person: Gray Peter (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-08-11 | Ordinary Shares | A | 3075 | $0.0 | Acquired | 17309 | Direct |
| 2023-08-14 | Ordinary Shares | S | 1241 | $138.1584 | Disposed | 16068 | Direct |
Footnotes
F1: Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2024.
F2: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.75 to $138.16. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.